FDA Votes "No" on Pfizer (PFE) Booster for 16+ Age Group, 2 Yes 16 No

September 17, 2021 3:31 PM EDT

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

(Updated - September 17, 2021 3:33 PM EDT)

The FDA voted against recommending a booster of Pfizer's (PFE) Covid vaccine, with just 2 out of 18 voting for approval and the other 16 voting 'no'.

The question asked during the FDA panel was, "Do the safety and effectiveness data from clinical trail C4591001 support approval of Comirnaty booster dose administered at least 6 months after completion of the primary series for use in individuals 16 years of age and older?"

Shares of Pfizer (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) traded lower throughout the day as the panel discussed the topic. Peer and mRNA vaccine maker Moderna (NASDAQ: MRNA) was also lower. Johnson & Johnson (NYSE: JNJ) was little changed.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Corporate News, FDA, Hot Corp. News, Hot FDA News, Trader Talk

Related Entities

FDA